Roche's business model is organised around two divisions—Pharmaceuticals and Diagnostics—that are managed as distinct businesses with separate P&Ls, leadership teams, and capital allocation frameworks, but that share a common strategic logic centred on the integrated personalised medicine platform. The Pharmaceuticals Division, which accounts for approximately 70% of group sales, develops and commercialises prescription medicines primarily in oncology, immunology, infectious diseases, neuroscience, and ophthalmology. The revenue model is the standard pharmaceutical commercial architecture: drugs are discovered or licensed, developed through clinical trials at a cost of typically $1–3 billion per approved molecule, approved by regulatory agencies, and then sold to hospitals, payers, and specialty pharmacies at prices that reflect the clinical value delivered, the competitive landscape, and the negotiated outcomes of complex reimbursement discussions with national health systems and private payers. In oncology—Roche's dominant therapeutic category—drugs are typically sold to hospital pharmacy departments at list prices subject to confidential rebates negotiated with payers, with pricing levels that reflect survival benefit, quality of life improvement, and the size of the addressable patient population. The product portfolio in Pharmaceuticals is anchored by a set of oncology biologics that have generated extraordinary cumulative revenues. Herceptin, Avastin, and Rituxan—the three cornerstone drugs acquired through Genentech—generated peak annual revenues approaching CHF 20 billion collectively before the onset of biosimilar competition from 2017 onward. The biosimilar cliff, which Roche management had been warning about and preparing for from approximately 2014, represents the largest revenue headwind a pharmaceutical company has faced from its own products and is the defining financial narrative of the 2017–2022 period. Management's response—accelerating the next generation of medicines, several of which are genuinely superior to the products they are replacing—is the central strategic execution challenge of the past several years. The next generation portfolio includes Tecentriq (atezolizumab), Roche's PD-L1 checkpoint immunotherapy competing in one of oncology's most competitive categories; Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine), both HER2-targeted agents that extend the franchise built on Herceptin's biological mechanism; Ocrevus (ocrelizumab) for multiple sclerosis, which has become one of the fastest-growing neurology drugs in history; Hemlibra (emicizumab) for haemophilia A, which has essentially replaced older factor replacement therapies for many patients; and Vabysmo (faricimab), a bispecific antibody for wet age-related macular degeneration and diabetic macular oedema that Roche's Genentech subsidiary developed as a potential market leader in ophthalmology. The Diagnostics Division's business model is structurally different from the pharmaceutical model in ways that create complementary financial characteristics. The installed base model—placing analysers in clinical laboratories under reagent rental or capital purchase agreements, then generating recurring reagent and consumable revenue for the life of the instrument—creates a high-visibility, high-margin recurring revenue stream that is substantially independent of drug pipeline risk. Once a laboratory has installed a Roche cobas analyser and trained its staff on its workflows, switching costs are significant: reagent recalibration, staff retraining, method validation, and regulatory reaccreditation all create inertia that sustains the installed base relationship for years or decades. The diagnostics revenue base is diversified across four major product areas: centralised and point-of-care laboratory diagnostics (clinical chemistry, immunoassay, haematology), molecular diagnostics (PCR, next-generation sequencing, digital pathology), tissue diagnostics (immunohistochemistry, in-situ hybridisation for tumour characterisation), and diabetes care monitoring. The centralised laboratory business—serving hospital and reference laboratories globally with high-volume automated analysers—is the largest by revenue and the most stable, while molecular diagnostics has been the fastest-growing segment and the one most affected by COVID-19 demand dynamics.